International Journal of Cancer Management

Published by: Neoscriber Demo Publisher
Crossmark

Comparison of Matrix Metalloproteinases 2 and 9 Levels in Saliva and Serum of Patients with Head and Neck Squamous Cell Carcinoma and Healthy Subjects

Zohreh Dalirsani ORCID 1 , Atessa Pakfetrat ORCID 1 , Zahra Delavarian ORCID 1 , Seyed Isaac Hashemy ORCID 2 , Leila Vazifeh Mostaan ORCID 3 , Marzieh Abdollahnejad 4 , Azar Fani Pakdel ORCID 5 , Elham Banihashemi 4 and Ala Ghazi ORCID 1 , *
Authors Information
1 Oral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3 Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4 Dentist, Mashhad, Iran
5 Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • International Journal of Cancer Management: May 31, 2019, 12 (5); e90249
  • Published Online: May 14, 2019
  • Article Type: Research Article
  • Received: February 4, 2019
  • Revised: April 22, 2019
  • Accepted: April 24, 2019
  • DOI: 10.5812/ijcm.90249

To Cite: Dalirsani Z , Pakfetrat A , Delavarian Z , Hashemy S I , Vazifeh Mostaan L, et al. Comparison of Matrix Metalloproteinases 2 and 9 Levels in Saliva and Serum of Patients with Head and Neck Squamous Cell Carcinoma and Healthy Subjects, Int J Cancer Manag. 2019 ; 12(5):e90249. doi: 10.5812/ijcm.90249.

Abstract
Copyright © 2019, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Gregoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v184-6. doi: 10.1093/annonc/mdq185. [PubMed: 20555077].
  • 2. SahebJamee M, Eslami M, AtarbashiMoghadam F, Sarafnejad A. Salivary concentration of TNFalpha, IL1 alpha, IL6, and IL8 in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2008;13(5):E292-5. [PubMed: 18449112].
  • 3. Stich HF, Mathew B, Sankaranarayanan R, Nair MK. Remission of precancerous lesions in the oral cavity of tobacco chewers and maintenance of the protective effect of beta-carotene or vitamin A. Am J Clin Nutr. 1991;53(1 Suppl):298S-304S. doi: 10.1093/ajcn/53.1.298S. [PubMed: 1985402].
  • 4. Streckfus CF, Dubinsky WP. Proteomic analysis of saliva for cancer diagnosis. Expert Rev Proteomics. 2007;4(3):329-32. doi: 10.1586/14789450.4.3.329. [PubMed: 17552913].
  • 5. Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, et al. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res. 2008;14(19):6246-52. doi: 10.1158/1078-0432.CCR-07-5037. [PubMed: 18829504]. [PubMed Central: PMC2877125].
  • 6. de Jong EP, Xie H, Onsongo G, Stone MD, Chen XB, Kooren JA, et al. Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions. PLoS One. 2010;5(6). e11148. doi: 10.1371/journal.pone.0011148. [PubMed: 20567502]. [PubMed Central: PMC2887353].
  • 7. Mroczko B, Lukaszewicz-Zajac M, Gryko M, Kedra B, Szmitkowski M. Clinical significance of serum levels of matrix metalloproteinase 2 (MMP-2) and its tissue inhibitor (TIMP-2) in gastric cancer. Folia Histochem Cytobiol. 2011;49(1):125-31. doi: 10.5603/FHC.2011.0018. [PubMed: 21526499].
  • 8. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases: A review. Crit Rev Oral Biol Med. 1993;4(2):197-250. doi: 10.1177/10454411930040020401. [PubMed: 8435466].
  • 9. Rosenthal EL, Matrisian LM. Matrix metalloproteases in head and neck cancer. Head Neck. 2006;28(7):639-48. doi: 10.1002/hed.20365. [PubMed: 16470875]. [PubMed Central: PMC2873217].
  • 10. Pramanik KK, Nagini S, Singh AK, Mishra P, Kashyap T, Nath N, et al. Glycogen synthase kinase-3beta mediated regulation of matrix metalloproteinase-9 and its involvement in oral squamous cell carcinoma progression and invasion. Cell Oncol (Dordr). 2018;41(1):47-60. doi: 10.1007/s13402-017-0358-0. [PubMed: 29134466].
  • 11. Jose D, Mane DR. Correlation of matrix metalloproteinase-9 expression with morphometric analysis of mucosal vasculature in oral squamous cell carcinoma, oral epithelial dysplasia, and normal oral mucosa. Int J Health Sci (Qassim). 2018;12(6):36-43. [PubMed: 30534042]. [PubMed Central: PMC6257871].
  • 12. Dowling P, Wormald R, Meleady P, Henry M, Curran A, Clynes M. Analysis of the saliva proteome from patients with head and neck squamous cell carcinoma reveals differences in abundance levels of proteins associated with tumour progression and metastasis. J Proteomics. 2008;71(2):168-75. doi: 10.1016/j.jprot.2008.04.004. [PubMed: 18617144].
  • 13. Shpitzer T, Bahar G, Feinmesser R, Nagler RM. A comprehensive salivary analysis for oral cancer diagnosis. J Cancer Res Clin Oncol. 2007;133(9):613-7. doi: 10.1007/s00432-007-0207-z. [PubMed: 17479291].
  • 14. Shpitzer T, Hamzany Y, Bahar G, Feinmesser R, Savulescu D, Borovoi I, et al. Salivary analysis of oral cancer biomarkers. Br J Cancer. 2009;101(7):1194-8. doi: 10.1038/sj.bjc.6605290. [PubMed: 19789535]. [PubMed Central: PMC2768098].
  • 15. Wang WL, Chang WL, Yeh YC, Lee CT, Chang CY, Lin JT, et al. Concomitantly elevated serum matrix metalloproteinases 3 and 9 can predict survival of synchronous squamous cell carcinoma of the upper aero-digestive tract. Mol Carcinog. 2013;52(6):438-45. doi: 10.1002/mc.21874. [PubMed: 22241750].
  • 16. Cheng D, Kong H, Li Y. Prognostic value of interleukin-8 and MMP-9 in nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 2014;271(3):503-9. doi: 10.1007/s00405-013-2580-3. [PubMed: 23749058].
  • 17. Ranuncolo SM, Matos E, Loria D, Vilensky M, Rojo R, Bal de Kier Joffe E, et al. Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer. 2002;94(5):1483-91. doi: 10.1002/cncr.10356. [PubMed: 11920505].
  • 18. Hong SD, Hong SP, Lee JI, Lim CY. Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. Oral Oncol. 2000;36(2):207-13. doi: 10.1016/S1368-8375(99)00088-3. [PubMed: 10745174].
  • 19. Cao XL, Xu RJ, Zheng YY, Liu J, Teng YS, Li Y, et al. Expression of type IV collagen, metalloproteinase-2, metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in laryngeal squamous cell carcinomas. Asian Pac J Cancer Prev. 2011;12(12):3245-9. [PubMed: 22471461].
  • 20. Lee SY, Park SY, Kim SH, Choi EC. Expression of matrix metalloproteinases and their inhibitors in squamous cell carcinoma of the tonsil and their clinical significance. Clin Exp Otorhinolaryngol. 2011;4(2):88-94. doi: 10.3342/ceo.2011.4.2.88. [PubMed: 21716956]. [PubMed Central: PMC3109333].
  • 21. Jordan RC, Macabeo-Ong M, Shiboski CH, Dekker N, Ginzinger DG, Wong DT, et al. Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin Cancer Res. 2004;10(19):6460-5. doi: 10.1158/1078-0432.CCR-04-0656. [PubMed: 15475433].
  • 22. Mohtasham N, Babakoohi S, Shiva A, Shadman A, Kamyab-Hesari K, Shakeri MT, et al. Immunohistochemical study of p53, Ki-67, MMP-2 and MMP-9 expression at invasive front of squamous cell and verrucous carcinoma in oral cavity. Pathol Res Pract. 2013;209(2):110-4. doi: 10.1016/j.prp.2012.11.002. [PubMed: 23273944].
  • 23. Patel BP, Shah PM, Rawal UM, Desai AA, Shah SV, Rawal RM, et al. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma. J Surg Oncol. 2005;90(2):81-8. doi: 10.1002/jso.20240. [PubMed: 15844188].
  • 24. Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck. 2007;29(6):564-72. doi: 10.1002/hed.20561. [PubMed: 17252594].
  • 25. Xu YP, Zhao XQ, Sommer K, Moubayed P. Correlation of matrix metalloproteinase-2, -9, tissue inhibitor-1 of matrix metalloproteinase and CD44 variant 6 in head and neck cancer metastasis. J Zhejiang Univ Sci. 2003;4(4):491-501. doi: 10.1631/jzus.2003.0491. [PubMed: 12861629].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments